Business Description
Immunovia AB
ISIN : SE0006091997
Total Employee Number:
17Compare
Compare
Traded in other countries / regions
IMMNOV.Sweden0G8X.UK1YR.GermanyIMMVF.USA IPO Date
2019-05-03Description
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 117.09 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -26.97 | |||||
Beneish M-Score | -6.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -51.9 | |||||
3-Year EBITDA Growth Rate | 43.2 | |||||
3-Year EPS without NRI Growth Rate | 46 | |||||
3-Year FCF Growth Rate | 55.7 | |||||
3-Year Book Growth Rate | -70.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.29 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 329.07 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
12-1 Month Momentum % | -61.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.05 | |||||
Quick Ratio | 3.04 | |||||
Cash Ratio | 2.92 | |||||
Days Inventory | 204.09 | |||||
Days Sales Outstanding | 26.41 | |||||
Days Payable | 4264.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -120 | |||||
Shareholder Yield % | -81.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.64 | |||||
Operating Margin % | -8695.65 | |||||
Net Margin % | -11594.78 | |||||
EBITDA Margin % | -8480.31 | |||||
FCF Margin % | -8153.06 | |||||
OCF Margin % | -8153.06 | |||||
ROE % | -355.16 | |||||
ROA % | -197.18 | |||||
ROIC % | -295.63 | |||||
3-Year ROIIC % | -58.41 | |||||
ROC (Joel Greenblatt) % | -10047.71 | |||||
ROCE % | -251.63 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.04 | |||||
PS Ratio | 94.5 | |||||
PB Ratio | 2.74 | |||||
Price-to-Tangible-Book | 2 | |||||
EV-to-EBIT | -0.9 | |||||
EV-to-EBITDA | -0.92 | |||||
EV-to-Revenue | 77.83 | |||||
EV-to-Forward-Revenue | 11.2 | |||||
EV-to-FCF | -0.95 | |||||
Price-to-GF-Value | 2 | |||||
Price-to-Median-PS-Value | 0.02 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2 | |||||
Earnings Yield (Greenblatt) % | -111.11 | |||||
FCF Yield % | -58.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IMMVF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunovia AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.098 | ||
| EPS (TTM) ($) | -0.025 | ||
| Beta | -0.364 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -0.91 | ||
| Volatility % | 61.59 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 0.02 | ||
| 12-1 Month Momentum % | -61.59 | ||
| 52-Week Range ($) | 0.02 - 0.05207 | ||
| Shares Outstanding (Mil) | 672.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunovia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunovia AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 127 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 36 days | ||
| General meeting for 2025 | 2026-05-13 11:00 | 0.02 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 15:00 | 0.02 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 08:30 | 0.02 (+0.00%) | ||
| Annual report for 2025 | 2026-04-10 | 0.02 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-24 15:00 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 08:30 | 0.02 (+0.00%) |
Show
Entries
Immunovia AB Frequently Asked Questions
What is Immunovia AB(IMMVF)'s stock price today?
The current price of IMMVF is $0.02. The 52 week high of IMMVF is $0.05 and 52 week low is $0.02.
When is next earnings date of Immunovia AB(IMMVF)?
The next earnings date of Immunovia AB(IMMVF) is 2026-08-06.
Does Immunovia AB(IMMVF) pay dividends? If so, how much?
Immunovia AB(IMMVF) does not pay dividend.
Guru Commentaries on OTCPK:IMMVF
No articles.
Press Release
Articles on Immunovia AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers